Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments June 23, 2026

https://www.fda.gov/drugs/news-events-human-drugs/financial-transparency-and-efficiency-prescription-drug-user-fee-act-biosimilar-user-fee-act-and-1?utm_medium=email&utm_source=govdelivery Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments Date: Tuesday, June 23, 2026; 1 - 2:30 p.m. ET The FDA is announcing its annual public meeting and opportunity for public comment on “Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments”. This public meeting is intended to meet performance commitments included in PDUFA VII, BsUFA III, and GDUFA III. These user fee programs were reauthorized as part of the FDA User Fee Reauthorization Act of 2022 signed by the President on September 30, 2022. https://events.gcc.teams.microsoft.com/event/7727cea2-45bc-45b4-844a-1f86f2772529@7d2fdb41-339c-4257-87f2-a665730b31fc/registration?utm_medium=email&utm_source=govdelivery